Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 777 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR October is National Dental Hygiene Month October 1, 2020 Scientists Focus on Fusion Proteins in Childhood Cancers August 4, 2020 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 “Oncometabolite” Neutralizes Immune Cells Near Tumors November 18, 2022 Load more HOT NEWS Studies Delve Deep into the Protein Machinery of Cancer Cells “Your Stories” Podcast: Amplifying Patient Voices Tovorafenib Approved for Some Children with Low-Grade Glioma FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma
